IL2 and metastatic melanoma: So far, only two drugs have been approved by the Food and Drug Administration (FDA) for the treatment of metastatic melanoma patients, the chemotherapeutic agent dacarbazine (DTIC) and the immunomodulator Interleukin-2 (IL-2).